I couldn’t be happier to see the work of my father, Mirko Beljanski, again receiving the recognition it deserves. Mirko Beljanski’s book “The Regulation of DNA Transcription and Replication”, originally published in 1983 by the prestigious scientific publisher Karger, will soon be released both in an e-book and printed format. These two will be the first part of an upcoming series of classical monographs of scientific importance, which remain of interest to the scholarly community.
The New York Times recently announced that nearly 50 years after the chemical was first used to clear foliage from jungles during the Vietnam War, the United States and Vietnam launched a $43-million joint cleanup effort to rid the nation of dioxin – or Agent Orange.
Agent Orange is actually the code name for one of the herbicides and defoliants used during the Vietnam War from 1961 to 1971, manufactured for the U.S. Department of Defense primarily by Monsanto Corporation and Dow Chemical. Contaminated with an extremely toxic dioxin compound, it was given its name from the color of the orange-striped 55 US gallon (208 l) barrels in which it was shipped. According to Wikipedia, during the Vietnam War, between 1962 and 1971, the United States military sprayed nearly 20,000,000 US gallons (80,000,000 l) of material containing chemical herbicides and defoliants mixed with jet fuel in Vietnam, eastern Laos and parts of Cambodia, as part of Operation Ranch Hand.(1)
In the eyes of many, the $43-million joint cleanup effort is too little, too late. The problem is one of liability. But when environmental factors are linked to disease, proof positive is sometimes hard to determine. While some American military studies have outlined connections between Agent Orange and myriad ailments, Dow Chemical maintains that the “very substantial body of human evidence on Agent Orange establishes that veterans’ illnesses are not caused by Agent Orange.” reports the NY times. And while VA and other Federal Government Departments and agencies have and continue to conduct extensive research evaluating the health effects of Agent Orange exposure on U.S. Veterans, little progress is being made towards indemnification of victims.
One of the possible reason for the lack of definitive scientific results is due to the fact that the mainstream Ames test used to classify cancer causing compounds ( Ames B, Lee F, Durston W. An improved bacterial test system for the detection and classification of mutagens and carcinogens. Proc Natl Acad Sci. 1973;70:782-786. ), is based on the belief that cancer formation is induced solely by mutation which transforms normal DNA into tumor DNA.
But there are too many exceptions to this mutagenetic theory and thanks to his own test, the Oncotest, Mirko Beljanski, PhD. was able to identify a class of compounds that were carcinogenic without exhibiting the mutagenic potential used by the Ames test to classify cancer causing compounds.
Dr Michael Schachter explains the motivation and mechanism behind the Oncotest very well:
“When Dr. Beljnski began his career as a molecular biologist in the early 50s at the Pasteur Institute in France, he was convinced that the recent discovery of the structure of DNA would open up major therapeutic possibilities that previously had not been imagined….
One of Dr. Beljanski’s key discoveries was that the secondary structure of DNA in cancer cells differed from normal DNA in that it contained some permanently open loops, as a result of carcinogenic substances interfering with the hydrogen bonding between the two strands of the double helix. These permanently separated sections allowed more carcinogenic substances to come between the two strands of the double helix and lead the DNA to uncontrollable replication and further deregulation of the cancer cell, resulting in rapid and uncontrollable growth of cancer cells. He referred to the cancerous DNA as destabilized DNA, since the hydrogen bonds did not hold the two strands together in a stable manner.
So, when cancerous DNA was exposed to carcinogenic substances, it replicated rapidly, while non-cancerous DNA replicated only slightly. This could be shown experimentally by adding substances to cancerous DNA or normal DNA and measuring either the increase in growth of the DNA or light absorption of the materials, as the more unstable the DNA, the more light that it would absorb (hyperchromicity). Once carcinogens had destabilized normal DNA to the point that it became permanently destabilized (had become cancerous DNA), further exposure to carcinogens would increase the destabilization, making the cancerous DNA unstable. In other words, cancers cells could become more aggressive and bizarre as they were exposed to more carcinogens.”
Edition Karger
These observations resulted in Beljanski developing a test to screen substances for carcinogenicity, which he patented in the 70’s as the “Oncotest”. Carcinogens resulted in the rapid replication of cancerous DNA, but affected normal DNA only slightly. Most importantly, the Oncotest revealed that a compound could show carcinogenic properties (by affecting DNA structure) without necessarily being a mutagen, which acts by altering DNA and protein sequences. The Oncotest was ultimately used to test hundreds of compounds for their effect on DNA stability and their potential to act as carcinogens.
Relatively low tech and inexpensive to perform, the Oncotest methodology was first patented by Mirko Beljanski and then included in his 1983 work «Regulation of DNA Replication and Transcription » published by Karger.
While the Karger edition is currently out of print, few reprints are still available through the Beljanski Foundation website, and the work will soon be republished by Demos Medical Publishing as the first of a series of classic monographs both in a printed and e-book format.
I am more excited that such remarkable and well-established publisher came to appreciate the value of my father’s work. Over the last 25 years Demos Medical Publishing has gained an international reputation as one of the last independent providers of high quality professional books and other scholarly resources for physicians and healthcare professionals. Demos Medical Publishing is also very committed to the mission of bridging the gap between consumers and the healthcare community and has been working tirelessly to promote the open spread of scientific knowledge in an accessible manner.
On September 2, CIRIS held its 21st annual picnic. As always, it was a day filled with kindness, friendship and hope. Pierrette WEIDLICH, the president of CIRIS Association was again the outstanding hostess, and on this occasion I wanted to take the opportunity to salute her courage and dedication to the association, matched only by her sense of organization. I would also like to thank all the active members of the association for their commitment and continued support of the scientific research.
Karger 1983
On the subject of scientific research, I was very proud to present, at the General Assembly of CIRIS, the latest results obtained by the Kansas University Medical Center. The recently published results demonstrated how the two extracts of Pao pereira and Rauwolfia vomitoria inhibit the development of both ovarian and pancreatic cancer cells. They also proved that the inhibition was selective, and did not affect the healthy cells. Most of this research was however devoted to the remarkable synergy of action between these extracts and traditional chemotherapy treatments. I also had the pleasure of publicly announcing the upcoming release of Mirko Beljanski’s book as an e-book.
Edition Trédaniel
These two days were also a great opportunity to announce the French translation of a book by Dr. Stephen Coles about Mirko Beljanski. This unique book written by an American doctor not only pays tribute to Mirko Beljanski’s work, but also explains in simple, understandable terms why Mirko Beljanski has changed the theory of carcinogenesis development and revealed new fascinating therapeutic approaches. A large part of the book is dedicated to the recent research conducted at both Columbia University and Cancer Treatment Centers of America. The English version of this bookis already available on the Beljanski Foundation’s website, and the French version will be available by the end of September through Trédaniel Editions as well as the French website of the Foundation.
Edition Freedom Press
Each year, the picnic is a great opportunity to hear new stories and testimonials about the Beljanski products. Some formely ill people shared their experience more 20 years after beginning supplementation, while others have just begun using them. This year we heard many testimonials and questions about autoimmune diseases including Multiple sclerosis (MS). An excellent doctor from Angoulême addressed a number of questions regarding medical matters, as well as sharing his experiences in preventative therapy and in palliative care.
On September 12, 2012 The Beljanski Foundation was featured on NBC New York Nightly News. Dr. John Hall and I were on the program to discuss the results of the Kansas University study on ovarian cancer for Ovarian Cancer Awareness Month.
The Kansas University study is only one of several studies supported by the Foundation and building on the legacy of my father, Mirko Beljanski’s, research. In addition to confirming the anti-cancer effect of the two plant extracts of Pao Pereira and Rauwolfia Vomitoria first discovered by my father, the Kansas scientists also found the botanicals worked especially well when combined with traditional chemotherapy treatment.
Other fascinating studies include research conducted by Columbia University, which concluded these extracts can help lower PSA levels and improve overall prostate health, and a study done by Cancer Treatment Centers of America, which after examining small RNA fragments developed by my father, determining that they can help maintain healthy platelet level for patients undergoing chemotherapy.
The work of the Beljanski Foundation is possible solely thanks to the generous donations of people like you who believe in its mission and share the commitment to making Mirko Beljanski’s research more widely available. Please help ensure the continuation of the current life saving research by making a tax-deductible donation through the foundation website.
Just as the lights of the television studio turned off, I set out for Florence, Italy to attend the “5 th European Congress for Integrative Medicine “( 2012 MACE ).
I had the distinct pleasure and honor of being invited to speak twice at this event. The first time, when I spoke about the small RNA fragments, was a great opportunity to present the results of the clinical trial at Cancer Treatment Centers of America. (CTCA)
On the other hand, the second lecture gave me more than an hour to present a comprehensive overview of the Beljanski approach to health.
I took this opportunity to discuss multiple studies carried out by Professor Beljanski himself on lymphoma cells at the Pasteur Institute, as well as the most recent studies carried by scientists working on prostate cancer at Columbia University and on ovarian and pancreatic cancers at Kansas University Medical Centre. What is remarkable is that each team was able to observe the same outstanding synergy of action between chemotherapy and the extracts of Pao Pereira and Rauwolfia Vomitoria, despite using completely different chemotherapy drugs each one having its own mode of action for different cancers.
These results can be explained by the fact that all the chemical molecules are involved in the destabilization of the DNA, while the Beljanski products block duplication of destabilized cell DNA.
This meta-analysis showing the efficiency of the who botanicals on even drug-resistant cells was very well received by the many doctors who attended the conferences.
I couldn’t be happier to see the work of my father, Mirko Beljanski, again receiving the recognition it deserves. Mirko Beljanski’s book “The Regulation of DNA Transcription and Replication”, originally published in 1983 by the prestigious scientific publisher Karger, will soon be released both in an e-book and printed format. These two will be the first part of an upcoming series of classical monographs of scientific importance, which remain of interest to the scholarly community.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
